Analysis shows gene therapy beneficial and likely cost-effective for patients with sickle cell disease

A modeling study comparing the cost-effectiveness of gene therapy versus common care for patients with sickle cell disease found that gene therapy is beneficial in this patient population and likely cost-effective if the price stays below $2 million per person. The findings are published in Annals of Internal Medicine.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart